Supporting fundraising post-IPO for Turn Therapeutics

Turn Therapeutics is a clinical-stage biotechnology company focused on dermatology, wound care, and infectious disease. They develop first-in-class topical cytokine-modulating therapeutics designed to deliver targeted anti-inflammatory effects without systemic immune exposure or injections.

Challenge

Our Approach

Results

The goal

Streamline fundraising among stakeholders.

As a public company, Turn Tx needed to build credibility through a consistent brand identity across all assets (pitch deck, website, MoA videos).

 

Website update

We developed the structure and visual assets for the website.

 

Video creation

We visualized a proprietary drug delivery platform to communicate its advantages to investors and partners.

 

Results

For J.P. Morgan 2026, we empowered Turn Therapeutics with refined investor-facing materials, ensuring their breakthrough science resonated with international investors:

- Website update
- Pitch deck update
- 2x3D MoA videos.

 

   Bradley Burnam

Founder/CEO Turn Therapeutics

"Want to thank NANOBOT GROUP for delivering game-changing materials ahead of the J.P. Morgan healthcare conference.

I cannot speak highly enough about longtime friend Yuriy Svidinenko or his team. They crunched keyboards through the holidays and remade our website & deck in record time.

If you haven’t seen the new digs, check em’ out! It’s science front and center over here. MOA’s and RCT’s and IL’s...all the acronyms!"